+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Share & Trends Analysis Report By Treatment, By Region, And Segment Forecasts, 2025 - 2030- Product Image
Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Share & Trends Analysis Report By Treatment, By Region, And Segment Forecasts, 2025 - 2030- Product Image
New

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Share & Trends Analysis Report By Treatment, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • December 2024
  • Region: Global
  • Grand View Research
  • ID: 6040979
Description Jump to:

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth & Trends

The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 9.96 billion by 2030, registering a CAGR of 9.6% from 2025 to 2030. Several factors such as rise in the number of blood and bone marrow related disorders, an increase in the geriatric population, wider adoption of novel therapeutics, and the emergence of biologics are driving the market.

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder. It is an ultra-rare disease with approximately 8,000 to 10,000 cases reported in North America and Europe. The life-threatening disease often manifests in three forms: thrombosis, persistent intravascular hemolysis, and pancytopenia. Although the information on its prevalence is scarce, PNH is estimated to affect more than 20,000 people worldwide with an incidence of about 1.3 per million annually and a prevalence of around 16 per million. PNH affects men and women equally. Although physical symptoms can begin at any age, they usually develop between 30-40 years of age.

Novel treatments including monoclonal antibodies, recombinant proteins, and cyclic peptides are gaining penetration in developed markets. However, the high cost of therapy with Soliris and other emerging pipeline drugs presents a barrier in adoption in developing regions. Blood transfusion and supportive care are anticipated to lose momentum during the forecast period due to adverse side effects and suboptimal efficacy.

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report Highlights

  • An estimated 5,000 - 6,000 people in the U.S. suffer from PNH, with approximately 450 new cases being reported annually
  • U.S. dominated the global PNH treatment market dominated with a significant revenue share in 2024 due to the high cost of treatment in the U.S., potential approval of a range of pipeline drugs, and adoption of novel therapeutics
  • Treatment with medication dominated the PNH market with a share of more than 85.3% in 2024. Apart from drugs, the stem cell transplant segment is projected to witness double-digit growth through the forecast period
  • Currently, 16 products are under clinical evaluation for PNH treatment in various stages of development. Promising pipeline candidates such as ALXN1210, Coversin, APL2, and RA101495 offer significant commercial potential post regulatory approval.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Treatment Business Analysis
4.1. Treatment Market Share, 2024 & 2030
4.2. Treatment Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Billion)
4.4. Medication
4.4.1. Medication Market, 2018 - 2030 (USD Billion)
4.5. Stem Cell Transplant
4.5.1. Stem Cell Transplant Market, 2018 - 2030 (USD Billion)
4.6. Blood Transfusion
4.6.1. Blood Transfusion Market, 2018 - 2030 (USD Billion)
4.7. Other Treatment Types
4.7.1. Other Treatment Types Market, 2018 - 2030 (USD Billion)
Chapter 5. Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Regional Estimates & Trend Analysis
5.1. Regional Market Share Analysis, 2024 & 2030
5.2. Regional Market Dashboard
5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
5.4. North America
5.4.1. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
5.4.2. U.S.
5.4.2.1. Key Country Dynamics
5.4.2.2. Regulatory Framework
5.4.2.3. Competitive Insights
5.4.2.4. U.S. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.4.3. Canada
5.4.3.1. Key Country Dynamics
5.4.3.2. Regulatory Framework
5.4.3.3. Competitive Insights
5.4.3.4. Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.4.4. Mexico
5.4.4.1. Key Country Dynamics
5.4.4.2. Regulatory Framework
5.4.4.3. Competitive Insights
5.4.4.4. Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.5. Europe
5.5.1. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
5.5.2. UK
5.5.2.1. Key Country Dynamics
5.5.2.2. Regulatory Framework
5.5.2.3. Competitive Insights
5.5.2.4. UK Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.5.3. Germany
5.5.3.1. Key Country Dynamics
5.5.3.2. Regulatory Framework
5.5.3.3. Competitive Insights
5.5.3.4. Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.5.4. France
5.5.4.1. Key Country Dynamics
5.5.4.2. Regulatory Framework
5.5.4.3. Competitive Insights
5.5.4.4. France Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.5.5. Italy
5.5.5.1. Key Country Dynamics
5.5.5.2. Regulatory Framework
5.5.5.3. Competitive Insights
5.5.5.4. Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.5.6. Spain
5.5.6.1. Key Country Dynamics
5.5.6.2. Regulatory Framework
5.5.6.3. Competitive Insights
5.5.6.4. Spain Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.5.7. Norway
5.5.7.1. Key Country Dynamics
5.5.7.2. Regulatory Framework
5.5.7.3. Competitive Insights
5.5.7.4. Norway Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.5.8. Denmark
5.5.8.1. Key Country Dynamics
5.5.8.2. Regulatory Framework
5.5.8.3. Competitive Insights
5.5.8.4. Denmark Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.5.9. Sweden
5.5.9.1. Key Country Dynamics
5.5.9.2. Regulatory Framework
5.5.9.3. Competitive Insights
5.5.9.4. Sweden Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
5.6. Asia Pacific
5.6.1. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.2. Japan
5.6.2.1. Key Country Dynamics
5.6.2.2. Regulatory Framework
5.6.2.3. Competitive Insights
5.6.2.4. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.3. China
5.6.3.1. Key Country Dynamics
5.6.3.2. Regulatory Framework
5.6.3.3. Competitive Insights
5.6.3.4. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.4. India
5.6.4.1. Key Country Dynamics
5.6.4.2. Regulatory Framework
5.6.4.3. Competitive Insights
5.6.4.4. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.5. South Korea
5.6.5.1. Key Country Dynamics
5.6.5.2. Regulatory Framework
5.6.5.3. Competitive Insights
5.6.5.4. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.6. Australia
5.6.6.1. Key Country Dynamics
5.6.6.2. Regulatory Framework
5.6.6.3. Competitive Insights
5.6.6.4. Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.7. Thailand
5.6.7.1. Key Country Dynamics
5.6.7.2. Regulatory Framework
5.6.7.3. Competitive Insights
5.6.7.4. Thailand Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.7. Latin America
5.7.1. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
5.7.2. Brazil
5.7.2.1. Key Country Dynamics
5.7.2.2. Regulatory Framework
5.7.2.3. Competitive Insights
5.7.2.4. Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.7.3. Argentina
5.7.3.1. Key Country Dynamics
5.7.3.2. Regulatory Framework
5.7.3.3. Competitive Insights
5.7.3.4. Argentina Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.8. MEA
5.8.1. MEA Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
5.8.2. South Africa
5.8.2.1. Key Country Dynamics
5.8.2.2. Regulatory Framework
5.8.2.3. Competitive Insights
5.8.2.4. South Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.8.3. Saudi Arabia
5.8.3.1. Key Country Dynamics
5.8.3.2. Regulatory Framework
5.8.3.3. Competitive Insights
5.8.3.4. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.8.4. UAE
5.8.4.1. Key Country Dynamics
5.8.4.2. Regulatory Framework
5.8.4.3. Competitive Insights
5.8.4.4. UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.8.5. Kuwait
5.8.5.1. Key Country Dynamics
5.8.5.2. Regulatory Framework
5.8.5.3. Competitive Insights
5.8.5.4. Kuwait Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 6. Competitive Landscape
6.1. Participant Overview
6.2. Company Market Position Analysis
6.3. Company Categorization
6.4. Strategy Mapping
6.5. Company Profiles/Listing
6.5.1. Alexion Pharmaceuticals, Inc.
6.5.1.1. Overview
6.5.1.2. Financial Performance
6.5.1.3. Treatment Benchmarking
6.5.1.4. Strategic Initiatives
6.5.2. Apellis Pharmaceuticals
6.5.2.1. Overview
6.5.2.2. Financial Performance
6.5.2.3. Treatment Benchmarking
6.5.2.4. Strategic Initiatives
6.5.3. Novartis AG
6.5.3.1. Overview
6.5.3.2. Financial Performance
6.5.3.3. Treatment Benchmarking
6.5.3.4. Strategic Initiatives
6.5.4. F. Hoffmann-La Roche Ltd
6.5.4.1. Overview
6.5.4.2. Financial Performance
6.5.4.3. Treatment Benchmarking
6.5.4.4. Strategic Initiatives
6.5.5. Genentech, Inc.
6.5.5.1. Overview
6.5.5.2. Financial Performance
6.5.5.3. Treatment Benchmarking
6.5.5.4. Strategic Initiatives
6.5.6. BioCryst Pharmaceuticals, Inc.
6.5.6.1. Overview
6.5.6.2. Financial Performance
6.5.6.3. Treatment Benchmarking
6.5.6.4. Strategic Initiatives
6.5.7. Regeneron Pharmaceuticals Inc.
6.5.7.1. Overview
6.5.7.2. Financial Performance
6.5.7.3. Treatment Benchmarking
6.5.7.4. Strategic Initiatives
6.5.8. Sanofi
6.5.8.1. Overview
6.5.8.2. Financial Performance
6.5.8.3. Treatment Benchmarking
6.5.8.4. Strategic Initiatives
6.5.9. Pfizer Inc.
6.5.9.1. Overview
6.5.9.2. Financial Performance
6.5.9.3. Treatment Benchmarking
6.5.9.4. Strategic Initiatives
6.5.10. Amgen Inc.
6.5.10.1. Overview
6.5.10.2. Financial Performance
6.5.10.3. Treatment Benchmarking
6.5.10.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global paroxysmal nocturnal hemoglobinuria treatment market, by region, 2018 - 2030 (USD Billion)
Table 4. Global paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 5. North America paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
Table 6. North America paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 7. U.S. paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 8. Canada paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 9. Mexico paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 10. Europe paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
Table 11. Europe paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 12. UK paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 13. Germany paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 14. France paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 15. Italy paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 16. Spain paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 17. Norway paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 18. Denmark paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 19. Sweden paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 20. Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
Table 21. Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 22. Japan paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 23. China paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018-2030 (USD Billion)
Table 24. India paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 25. Australia paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 26. South Korea paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 27. Thailand paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 28. Latin America paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
Table 29. Latin America paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 30. Brazil paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 31. Argentina paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 32. Middle East & Africa paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
Table 33. Middle East & Africa paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 34. South Africa paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 35. Saudi Arabia paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 36. UAE paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 37. Kuwait paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
List of Figures
Fig. 1 Paroxysmal Nocturnal Hemoglobinuria Treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Treatment outlook (USD Billion)
Fig. 10 Competitive landscape
Fig. 11 Paroxysmal Nocturnal Hemoglobinuria Treatment market dynamics
Fig. 12 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Porter’s five forces analysis
Fig. 13 Paroxysmal Nocturnal Hemoglobinuria Treatment market: PESTLE analysis
Fig. 14 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Treatment segment dashboard
Fig. 15 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Treatment market share analysis, 2024 & 2030
Fig. 16 Medication market, 2018 - 2030 (USD Billion)
Fig. 17 Stem cell transplant market, 2018 - 2030 (USD Billion)
Fig. 18 Blood transfusion market, 2018 - 2030 (USD Billion)
Fig. 19 Other treatment types market, 2018 - 2030 (USD Billion)
Fig. 20 Paroxysmal Nocturnal Hemoglobinuria Treatment market revenue, by region
Fig. 21 Regional marketplace: Key takeaways
Fig. 22 North America paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 23 U.S. country dynamics
Fig. 24 U.S. paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 25 Canada country dynamics
Fig. 26 Canada paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 27 Mexico country dynamics
Fig. 28 Mexico paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 29 Europe paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 30 UK country dynamics
Fig. 31 UK paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 32 Germany country dynamics
Fig. 33 Germany paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 34 France country dynamics
Fig. 35 France paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 36 Italy country dynamics
Fig. 37 Italy paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 38 Spain country dynamics
Fig. 39 Spain paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 40 Norway country dynamics
Fig. 41 Norway paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 42 Sweden country dynamics
Fig. 43 Sweden paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 44 Denmark country dynamics
Fig. 45 Denmark paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 46 Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 47 Japan country dynamics
Fig. 48 Japan paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 49 China country dynamics
Fig. 50 China paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 51 India country dynamics
Fig. 52 India paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 53 Australia country dynamics
Fig. 54 Australia paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 55 South Korea country dynamics
Fig. 56 South Korea paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 57 Thailand country dynamics
Fig. 58 Thailand paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 59 Latin America paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 60 Brazil country dynamics
Fig. 61 Brazil paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 62 Argentina country dynamics
Fig. 63 Argentina paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 64 MEA paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 65 South Africa country dynamics
Fig. 66 South Africa paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 67 Saudi Arabia country dynamics
Fig. 68 Saudi Arabia paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 69 UAE country dynamics
Fig. 70 UAE paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 71 Kuwait country dynamics
Fig. 72 Kuwait paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
Fig. 73 Company categorization
Fig. 74 Company market position analysis
Fig. 75 Strategic framework

Companies Mentioned

  • Alexion Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Pfizer Inc.
  • Amgen Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedDecember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.75 billion
Forecasted Market Value ( USD ) by 2030 $ 9.96 billion
Compound Annual Growth Rate9.6%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test, Treatment - Global Forecast 2025-2030 - Product Image

Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test, Treatment - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2024 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria Market - Product Image

Paroxysmal Nocturnal Hemoglobinuria Market

  • Report
  • 200 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Paroxysmal Nocturnal Hemoglobinuria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 129 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.